Use of the Cyclops dry powder inhaler by patients with Parkinson's disease after inhalation instruction.

Use of the Cyclops dry powder inhaler by patients with Parkinson's disease after inhalation instruction. - Use of the Cyclops by Parkinson's patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55067

Enrollment

Registered

2019-12-09

Start date

2020-08-11

Completion date

Unknown

Last updated

2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Diagnosed with Parkinson's disease by a nerologist; - At least 18 years of age; - Signed informed consent.

Exclusion criteria

Exclusion criteria: - Not able to understand inhalation instruction (within a maximum of 30 minuten). - Previously participated in the Parkinson DPI-1, DPI-2 or DPI-3 studie (prior knowledge of the inhalation maneuver); - Active pulmonary disease.

Design outcomes

Primary

Measure	Time frame
The main study parameter is to investigate whether Parkinson*s patients are able to reproduce an optimal inhalation technique for the Cyclops® inhaler by measuring the pressure drop (kPa), breath hold time (sec.) and inhaled volume (L) after first and second inhalation instruction.	—

Secondary

Measure	Time frame
The secondary study parameter is to investigate whether Parkinson*s patients perform the correct steps in accordance with the patient instruction card with the Cyclops® inhaler after first and second inhalation instruction.	—

Countries

Netherlands

Outcome results